Andrade Robert 4

What Happened Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals (FENC), received 1,703 shares on May 31, 2026. The Form 4 reports an acquisition (code A) at $0.00 per share (total reported cost $0), indicating these were restricted shares released/vested rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-31 (acquisition code A — award/grant)
• Shares received: 1,703; acquisition price reported: $0.00; reported total $0
• Filing date: 2026-06-01 — filing appears timely (within Form 4 reporting window)
• Footnote: "Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025."
• No sale, 10b5-1 plan, or tax-withholding sale reported in the provided filing summary
• Shares owned after the transaction are not specified in the information provided

Context This transaction reflects the vesting/release of previously granted restricted stock as part of executive compensation. It is a receipt of shares (not a purchase or sale) and is a routine compensation event rather than a direct market signal. No immediate sale of these shares was reported on the Form 4.